The BLOC1S3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This product provides a loss-of-function model for the BLOC1S3 gene, which encodes a subunit of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Through CRISPR/Cas9-mediated gene disruption, the polyclonal knockout population enables investigation of BLOC1S3 function in a physiologically relevant epithelial context.
The A-549 cell line is a widely used model of human non-small cell lung cancer (NSCLC), characterized by adherent epithelial morphology and utility in cancer biology, drug response, and epithelial function studies. Originating from a lung adenocarcinoma, A-549 cells retain critical signaling networks relevant to NSCLC, providing a robust platform for examining gene function in tumor biology. The knockout of BLOC1S3 in these cells allows exploration of its roles in pathways that may intersect with cancer-associated processes.
BLOC1S3 is a core component of the BLOC-1 complex, which regulates vesicular trafficking from early endosomes to lysosome-related organelles. The BLOC-1 complex functionally interacts with the AP-3 adaptor and clathrin to direct cargo such as tyrosinase and melanogenic enzymes to maturing melanosomes, and to facilitate platelet dense granule formation by sorting platelet cargoes. Knockout of BLOC1S3 disrupts BLOC-1 function, impairing endosomal sorting and leading to defective biogenesis of organelles such as melanosomes and platelet dense granules. Downstream consequences include mislocalization of lysosomal proteins and reduced trafficking of melanosomal membrane proteins like TYRP1.
In the A-549 cellular context, BLOC1S3 knockout offers a unique tool to dissect the interplay between lysosome-related organelle biogenesis and epithelial cancer cell biology. While A-549 cells are not of melanocytic or platelet lineage, they possess a conserved endosomal-lysosomal system, and disruption of BLOC-1 may illuminate how trafficking defects contribute to Hermansky-Pudlak syndrome type 8??a disorder featuring oculocutaneous albinism, bleeding diathesis, and pulmonary fibrosis. This model also permits investigation of lysosomal dysfunction in lung adenocarcinoma.
The BLOC1S3 Knockout A-549 Polyclonal Cells support a range of research applications, including studies of lysosome-related organelle biogenesis, endosomal trafficking defects, and Hermansky-Pudlak syndrome modeling. They can be employed in immunofluorescence assays to assess LAMP1/LAMP2 distribution, western blotting to monitor lysosomal enzyme maturation, RT-qPCR for verifying BLOC1S3 disruption, endocytosis assays to evaluate trafficking dynamics, and organelle trafficking analysis. Additionally, these cells serve as a platform for testing therapeutic strategies for lysosomal disorders. For further information, please contact Ascent Research.
